Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
The project funding will be done through a mix of internal accruals and debts.
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Subscribe To Our Newsletter & Stay Updated
